ArticlemSphere2020
Disruption of Cross-Feeding Inhibits Pathogen Growth in the Sputa of Patients with Cystic Fibrosis.
Article in mSphere, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 47 citations in OpenAlex.
- Differential Metabolite Production Underlies Disruption of the Cystic Fibrosis Airway Microbiota by Pathogens.bioRxiv : the preprint server for biology · 2026Article
- When Culture Results Don't Tell the Whole Story: A Practical Review of Antibiotics Pitfalls for Clinical Decision-Making.Infectious diseases and therapy · 2026Review
- Gastrointestinal infection caused by five different strains of Aeromonas caviae and one of Aeromonas veronii: case report and review of the literature.BMC infectious diseases · 2026Review
- Anaerobic microbiota promote pathogen association with the airway epithelium.Journal of medical microbiology · 2026Article
- Systematic metaproteomics mapping reveals functional and ecological landscapes of Ex vivo human gut microbiota responses to therapeutic drugs.Nature communications · 2025Article
- Pharmacodynamics of interspecies interactions in polymicrobial infections.NPJ biofilms and microbiomes · 2025Article
- Integrating sequencing methods with machine learning for antimicrobial susceptibility testing in pediatric infections: current advances and future insights.Frontiers in microbiology · 2025Review
- Metabolic interplay betweenmBio · 2024Article
- Iron content of commercial mucin contributes to compositional stability of a cystic fibrosis airway synthetic microbiota community.bioRxiv : the preprint server for biology · 2024Article
- Microbial community organization designates distinct pulmonary exacerbation types and predicts treatment outcome in cystic fibrosis.Nature communications · 2024Observational
- We have a community problem.Journal of bacteriology · 2024Article
- Microbial community organization designates distinct pulmonary exacerbation types and predicts treatment outcome in cystic fibrosis.Research square · 2024Article
- Co-occurring microflora and mucin driveISME communications · 2024Article
- Translating eco-evolutionary biology into therapy to tackle antibiotic resistance.Nature reviews. Microbiology · 2023Review
- Development of a Polymicrobial Checkerboard Assay as a Tool for Determining Combinatorial Antibiotic Effectiveness in Polymicrobial Communities.Antibiotics (Basel, Switzerland) · 2023Article
- Community composition shapes microbial-specific phenotypes in a cystic fibrosis polymicrobial model system.eLife · 2023Article
- Limited Impact of SARS-CoV-2 on the Human Naso-Oropharyngeal Microbiota in Hospitalized Patients.Microbiology spectrum · 2022Article
- Antibiotics Drive Expansion of Rare Pathogens in a Chronic Infection Microbiome Model.mSphere · 2022Article
- Physiology and pathophysiology of human airway mucus.Physiological reviews · 2022Review
- The changing landscape of the cystic fibrosis lung environment: From the perspective of Pseudomonas aeruginosa.Current opinion in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
A critical limitation in the management of chronic polymicrobial infections is the lack of correlation between antibiotic susceptibility testing (AST) and patient responses to therapy. Underlying this disconnect is our inability to accurately recapitulate the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.